Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hemoglobin

Showing results (801-810 of 2,379) with videos related to

Pageof 238
Sort By:
Hemoglobin|March 17, 2005
Prevalence of alpha-globin gene deletions among patients with unexplained microcytosis in a North-American populationJulie Bergeron, Xiaoduan Weng, Louise Robin, et al.
Hemoglobin|March 17, 2005
Hb Tak: a beta chain elongation at the end of the beta chain, in a TaiwaneseMu-Chin Shih, Kang-His Wu, Su-Ching Liu, et al.
Hemoglobin|March 17, 2005
Thalassemia intermedia associated with complex interaction of Hb Beijing [alpha16(A14)Lys-->Asn] and Hb E [beta26(B8)Glu-->Lys] with a deletional alpha-thalassemia-1 in a Thai familySupan Fucharoen, Sunisa Chunpanich, Kanokwan Sanchaisuriya, et al.
Hemoglobin|January 1, 1991
Hb Yokohama [beta 31 (B13)Leu----Pro] detected as a de novo mutation in a Yugoslavian boyD Plaseska, L Janković, A J Dimovski, et al.
Hemoglobin|January 1, 1991
Hb Coimbra or alpha 2 beta (2)99(G1)Asp----Glu, a newly discovered highoxygen affinity variantG P Tamagnini, M L Ribeiro, V Valente, et al.
Hemoglobin|January 1, 1991
Application of reversed phase high performance liquid chromatography and plasma desorption mass spectrometry for the characterization of a hemoglobin variantO N Jensen, P Roepstorff
Hemoglobin|February 16, 2008
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiproneAnnita Kolnagou, Yiannis Michaelides, Christos Kontos, et al.
Hemoglobin|February 16, 2008
Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatmentNatalie Tourkantoni, Miranda Athanassiou-Metaxa, Dimitrios Zafiriou, et al.
Hemoglobin|February 16, 2008
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocolsAnnita Kolnagou, Charalambos Economides, Eleni Eracleous, et al.
Hemoglobin|February 16, 2008
Iron out-of-balance: a risk factor for acute and chronic diseasesEugene D Weinberg
Pageof 238

Showing results (801-810 of 2,379) with videos related to

Sort By:
Pageof 238
Hemoglobin|March 17, 2005
Prevalence of alpha-globin gene deletions among patients with unexplained microcytosis in a North-American populationJulie Bergeron, Xiaoduan Weng, Louise Robin, et al.
Hemoglobin|March 17, 2005
Hb Tak: a beta chain elongation at the end of the beta chain, in a TaiwaneseMu-Chin Shih, Kang-His Wu, Su-Ching Liu, et al.
Hemoglobin|March 17, 2005
Thalassemia intermedia associated with complex interaction of Hb Beijing [alpha16(A14)Lys-->Asn] and Hb E [beta26(B8)Glu-->Lys] with a deletional alpha-thalassemia-1 in a Thai familySupan Fucharoen, Sunisa Chunpanich, Kanokwan Sanchaisuriya, et al.
Hemoglobin|January 1, 1991
Hb Yokohama [beta 31 (B13)Leu----Pro] detected as a de novo mutation in a Yugoslavian boyD Plaseska, L Janković, A J Dimovski, et al.
Hemoglobin|January 1, 1991
Hb Coimbra or alpha 2 beta (2)99(G1)Asp----Glu, a newly discovered highoxygen affinity variantG P Tamagnini, M L Ribeiro, V Valente, et al.
Hemoglobin|January 1, 1991
Application of reversed phase high performance liquid chromatography and plasma desorption mass spectrometry for the characterization of a hemoglobin variantO N Jensen, P Roepstorff
Hemoglobin|February 16, 2008
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiproneAnnita Kolnagou, Yiannis Michaelides, Christos Kontos, et al.
Hemoglobin|February 16, 2008
Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatmentNatalie Tourkantoni, Miranda Athanassiou-Metaxa, Dimitrios Zafiriou, et al.
Hemoglobin|February 16, 2008
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocolsAnnita Kolnagou, Charalambos Economides, Eleni Eracleous, et al.
Hemoglobin|February 16, 2008
Iron out-of-balance: a risk factor for acute and chronic diseasesEugene D Weinberg
Pageof 238